Fasinumab

Source: Wikipedia, the free encyclopedia.
Fasinumab
Monoclonal antibody
Type?
SourceHuman
TargetHNGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6406H9896N1700O2026S46
Molar mass144618.27 g·mol−1

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]

This drug was developed in collaboration by

Teva Pharmaceutical Industries and Regeneron Pharmaceuticals
.

It is currently at Phase III trials (NCT03245008, NCT02683239, and NCT03161093).[3]

See also

References

  1. ^ "Fasinumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  2. PMID 25210473
    .
  3. S2CID 244509341
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Fasinumab&oldid=1177181424"